A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)

The purpose of this research is to test the effectiveness and safety of the study drugs (Avutometinib and defactinib), and see what effects (good and bad) these drugs have on you and others with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, and other solid gynecological tumors. The idea behind taking two drugs is to approach the cancer from different directions to increase the chance of reducing the tumor size. This study expands upon positive findings from an ongoing study involving low-grade serous ovarian cancer. This study is aimed at determining if similarly, positive results may be achieved in other gynecological cancers.